الفهرس 
ANATOMYOnly 14 pages are availabe for public view
 |  | from | 108 |  |  |
| | | from | 108 | | |
Abstract
Prostate-specific antigen (PSA) is a protein produced by normal prostate cells. This enzyme participates in the dissolution of the seminal fluid coagulum and plays an important role in fertility. The highest amounts of PSA are found in the seminal fluid; some PSA escapes the prostate and can be found in the serum.
Prostate cancer (PC) is the second most common cancer and the fifth leading cause of cancer-associated mortality among men worldwide. Screening for prostate cancer with serum prostate-specific antigen (PSA) aims to detect prostate cancer at an early, intervenable stage amenable to curative treatment and reduction in overall and disease-specific mortality.
For the detection of prostate cancer, an elevated serum prostate-specific antigen is the most common laboratory abnormality, as the majority of men with early prostate cancer have no symptoms. However, prostate-specific antigen is clinically imprecise as benign and malignant processes both, can elevate the serum marker. Despite the risks and benefits of serum PSA screening, it is the most useful tool available for the detection of early prostate cancer, giving affected individuals the best chance for cure.
PC screening is still controversial, as the potential benefits and harms continue to be debated among health professionals. The controversy over PSA screening includes the possibilities of detecting insignificant PCs that would never lead to death (over-diagnosis) and then treating these PCs (over-treatment). Other issues include cost and convenience, which are possible reasons why the rate of PSA screening is low.
In this study, we aimed to determine accuracy, sensitivity, specificity of one-step PSA test (Fortel Test®) FDA approved in comparison to a conventional quantitative assay.
This Prospective cohort clinical study was conducted at tertiary care hospital at Urology Department, Outpatient clinic, Faculty of Medicine, Ain Shams University from January 2022 till June 2022 and performed on a total of 150 patients who were above 50 years old or above 40 years old with family history of prostate cancer.
The current study revealed that Median (IQR) of PSA value was 3.8 (2.3–8). The clinical PSA value was positive in 78 cases (52%) and negative in 72 cases (48%) and the Fortel PSA test value was positive in 77 cases (51.3%) and negative in 73 cases (48.7%).